
As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for advanced kidney disease.
Results from the PIONEER trials program indicate that patient-reported outcomes were generally similar between oral semaglutide and comparators, with few exceptions.
Click PLAY to watch the video abstract.
Click
Click





